Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Lima | Healthcare | Pharmaceuticals | PEN 2.64T | 85.4x | 1.32 | PEN 3,146.62 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Lima | Healthcare | Pharmaceuticals | PEN 1.31T | 24x | -0.45 | PEN 556.96 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Lima | Healthcare | Pharmaceuticals | PEN 1.14T | 60.5x | -2.86 | PEN 705.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Lima | Healthcare | Pharmaceuticals | PEN 960.33B | 21.4x | 0.13 | PEN 382.98 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Lima | Healthcare | Pharmaceuticals | PEN 542.45B | 34.1x | -0.57 | PEN 95.69 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Lima | Healthcare | Pharmaceuticals | PEN 425.85B | 910.7x | -9.31 | PEN 358.84 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Lima | Healthcare | Pharmaceuticals | PEN 420.02B | -15.5x | 0.09 | PEN 225.17 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |